Patent · US Active

ErbB receptor inhibitors

US10822334B2 · kind B2 · utility

3Cited by

0References

6Claims

0Family size

Inventors

Zhengtao LI · Shanghai, CN
Wei Zhong · Pullman, US
Jiabing Wang · Lansdale, US
Qingbei Zeng · Shanghai, CN
Honchung Tsui · Shanghai, CN
Zhenfan Yang · Shanghai, CN
Xiaolin Zhang · Singapore, SG

Key dates

Filing date	Jun 24, 2020
Grant date	Nov 3, 2020
Priority date	—
Expiry date	Jun 24, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.